Cytomegalovirus prophylaxis and treatment following bone marrow transplantation

Annals of Pharmacotherapy

Volumn 30, Issue 11, 1996, Pages 1277-1290

  Tsinontides, Athos C ^a,b   Bechtel, Thomas P ^a,c  

^a OHIO STATE UNIVERSITY   (United States)

^b NICOSIA GENERAL HOSPITAL   (Cyprus)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN;

BACTERIAL INFECTION; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; EARLY DIAGNOSIS; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; INTERSTITIAL PNEUMONIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PANCYTOPENIA; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0029959831     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603001113     Document Type: Review

References (79)

1. Strada RJ. Clinical patterns and treatment of cytomegalovirus infection after solid-organ transplantation. Transplant Proc 1993;25(suppl 4):S15-21.
2. Ho M. Epidemiology of cytomegalovirus infections. Rev Infect Dis 1990;12(suppl 7):S701-10.
3. Hurd DD. Bone marrow transplantation for cancer: an overview. Recent Results Cancer Res 1993;132:1-13.
4. Bortin MM, Horowitz MM, Rimm AA. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. Ann Intern Med 1992:116:505-12.
5. Kerman NA, Bartsch G, Ash R, Beatty PG, Champlin R, Filipovich A, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993;328:593-602.
6. Poliquin CM. Post-bone marrow transplant patient management. Yale J Biol Med 1990;63:495-502.
7. Hiemenz JW, Greene JN. Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. Hematol Oncol Clin North Am 1993;7:961-1002.
8. Winston DJ, Ho WG, Champlin RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990;12(suppl 7):S776-92.
9. Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 1984;38:465-68.
10. Gluckman E, Traineau R, Devergie A, Esperou-Bourdeau H, Hirsch I. Prevention and treatment of CMV infection after allogeneic bone marrow transplant. Ann Hematol 1992;64(suppl A):158-64.
11. Schmidt GM. Treatment and prophylaxis of cytomegalovirus infection after bone marrow transplantation. Recent Results Cancer Res 1993;132: 161-74.
12. Enright H, Haake R, Weisdorf D, Ramsay N, McGlave P, Kersey J, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation 1993;55:1339-46.
13. Grañena A, Carreras E, Rozman C, Salgado C, Sierra J, Algara M, et al. Interstitial pneumonitis after BMT: 15 years experience in a single institution. Bone Marrow Transplant 1993;11:453-58.
14. Wingard JR, Chen DY, Burns WH, Fuller DJ, Braine HG, Braine HG, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood 1988;71:1432-7.
15. Reusser P, Fisher LD, Buckner CD, Thomas ED, Meyers JD. Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990; 75:1888-94.
16. Reed EC. Infectious complications during autotransplantation. Hematol Oncol Clin North Am 1993;7:717-35.
17. Rubie H, Attal M, Campardou AM, Gayet-Mengelle C, Payen C, Sanguignol F, et al. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products. Bone Marrow Transplant 1993;11:209-14.
18. Bacigalupo A, Tedone E, Sanna MD, Moro F, Van Lint MT, Grazi G, et al. CMV infections following allogeneic BMT: risk factors, early treatment and correlation with transplant related mortality. Haematologica 1992;77:507-13.
19. Prentice HG, Gluckman E, Powels RL, Ljungman P, Milpled N, Fernandez Ranada MJ, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994;343:749-53.
20. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia JA, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants. N Engl J Med 1991;324:1005-11.
21. Goodrich JM, Mori M, Gleaves CA, Du Mond C, Cays M, Ebeling DF, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation. N Engl J Med 1991; 325:1601-7.
22. Winston DJ, Ho WG, Lin CH, Bartoni K, Budinger MD, Gale RP, et al. Intravenous immune globulin for the prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 1987;106:12-8.
23. Winston DJ, Pollard RB, Ho WG, Gallagher JG, Rasmussen LE, Huang SN, et al. Cytomegalovirus immune plasma in bone marrow transplant recipients. Ann Intern Med 1982;97:11-8.
24. Einsele H, Steidle M, Vallbracht A, Saal JG, Ehninger G, Muller CA. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as demonstrated by the polymerase chain reaction technique. Blood 1991;77:1104-10.
25. Ljungman P, De Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, et al. Practices for the cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the Working Party for Infectious Diseases of the EBMT. Bone Marrow Transplant 1993;12:399-403.
26. Winston DJ, Ho WG, Bartoni K, Champlin RE. Intravenous immunoglobulin and CMV-seronegative blood products for prevention of CMV infection and disease in bone marrow transplant recipients. Bone Marrow Transplant 1993;12:283-8.
27. Bowden RA, Sayers M, Flournoy N, Newton B, Banaji M, Thomas ED, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N Engl J Med 1986;314:1006-10.
28. Sullivan KM, Kopecky KJ, Jocom J, Fisher L, Buckner CD, Meyers JD, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 1990;323: 705-12.
29. Sayers MH, Anderson KC, Goodnough LT, Kurtz SR, Lane TA, Pisciotto P, et al. Reducing the risk for transfusion-transmitted cytomegalovirus infection. Ann Intern Med 1992:116:55-62.
30. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993;118:173-8.
31. Rowe JM, Ciobanu N, Ascensao J, Stadtmauer EA, Weiner RS, Schenkein DP, et al. Recommended guidelines for the management of autologous and allogeneic bone marrow transplantion: a report from the Eastern Cooperative Oncology Group (ECOG). Ann Intern Med 1994;120: 143-58.
32. Keating MR. Antiviral agents from the Symposium on Antimicrobial Agents. Part VI. Mayo Clin Proc 1992;67:160-78.
33. Gluckman E, Devergie A, Melo R, Nebout T, Lotsberg J, Zhao XM, et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983;2:706-8.
34. Lundgren G, Wilczek H, Lonnqvist B, Lindholm A, Wahren B, Ringden O. Acyclovir prophylaxis in bone marrow transplant recipients. Scand J Infect Dis 1985;47:137-44.
35. Selby PJ, Powles RL, Easton D, Perren TJ, Stolle K, Jameson B, et al. The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation. Br J Cancer 1989;59:434-8.
36. Winston DJ, Ho WG, Bartoni K, Du Mond C, Ebeling DF, Buhles WC, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993; 118:179-84.
37. Fletcher CV, Balfour HH Jr. Evaluation of ganciclovir for cytomegalovirus disease. DICP Ann Pharmacother 1989;23:5-12.
38. Barge AJ. A review of the efficacy and tolerability of recombinant haematopoietic growth factors in bone marrow transplantation. Bone Marrow Transplant 1993;11(suppl):S1-11.
39. Fouillard L, Gorin NC, Laporte JP, Eugene-Jolchine I, Isnard F, Najman A. GM-CSF and ganciclovir for cytomegalovirus infection after autologous bone-marrow transplantation (letter). Lancet 1989;2:1273.
40. Minor JR, Baltz JK. Foscarnet sodium. DICP Ann Pharmacother 1991; 25:41-7.
41. Deray G, Martinez F, Katlama B, Beaufils H, Danis M, Rozenheim M, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989;9:316-21.
42. Ringden O, Lonnqvist B, Aschan J, Sundberg B. Foscarnet prophylaxis in marrow transplant recipients (letter). Bone Marrow Transplant 1989; 4:713.
43. Reusser P, Gambertoglio JG, Lilleby K, Meyers JD. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. J Infect Dis 1992;166:473-9.
44. Erice A, Chou S, Biron KK, Stanta SC, Balfour HH, Jordan MC. Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients. N Engl J Med 1989;320:289-93.
45. Drew WL, Miner RC, Busch DF, Follansbee SE, Gullett J, Mehalko SG, et al. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection. J Infect Dis 1991;163:716-9.
46. Drobyski WR, Knox KK, Carrigan DR, Ash RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation (brief report). Trasplantation 1991;52:155-7.
47. Knox KK, Drobyski WR, Carrigan DR. Cytomegalovirus isolate resistant to ganciclovir and foscarnet from a marrow transplant patient (letter). Lancet 1991;337:1292-3.
48. Slavin MA, Bindra RR, Gleaves CA, Bettnger MB, Bowdeb RA. Ganciclovir sensitivity of cytomegalovirus at diagnosis and during treatment of cytomegalovirus pneumonia in marrow transplant recipients. Antimicrob Agents Chemother 1993;37:1360-3.
49. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulin. Drug Saf 1993;9:254-62.
50. Snydman DR. Prevention of cytomegalovirus-associated diseases with immunoglobulin. Transplant Proc 1991;23(suppl 3):S131-5.
51. Ho M, Cytomegalovirus. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990:1159-72.
52. Winston DJ, Ho WG, Lin CH, Budinger MD, Champlin RE, Gale RP. Intravenous immunoglobulin for modification of cytomegalovirus infections associated with bone marrow transplantation. Preliminary results of a controlled trial. Am J Med 1984;76(3A):128-33.
53. Wolff SN, Fay JW, Herzig RH, Greer JP, Dummer S, Brown RA, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern Med 1993;118:937-42.
54. Meyers JD, Leszczynski J, Zaia JA, Flournoy, Newton B, Snydman DR, et al. Prevention of cytomegalovirus infection by cytomegalovirus immune globulin after marrow transplantation. Ann Intern Med 1983;98: 442-6.
55. Codie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Am J Med 1984;76(3A):134-41.
56. Kubaneck B, Ernst P, Ostendorf P, Schafer U, Wolf H. Preliminary data of a controlled trial of intravenous hyperimmune globulin in the prevention of cytomegalovirus infection in bone marrow transplant recipients. Transplant Proc 1985;17:468-9.
57. Ringden O, Pihlstedt P, Volin L, Nikoskelainen J, Lonnqvist B, Ruutu P, et al. Failure to prevent cytomegalovirus infection by cytomegalovirus hyperimmune plasma: a randomized trial by the Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1987;2:299-305.
58. Bowden RA, Fisher L, Rogers K, Cays M, Meyers JD. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991;164:483-7.
59. Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, et al. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. Bone Marrow Transplant 1988;3:559-66.
60. Meyers JD, McGuffin RW, Neiman PE, Singer JW, Thomas ED. Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J Infect Dis 1980;141: 555-62.
61. Wade JC, Hintz M, McGuffin RW, Springmeyer SC, Connor JD, Meyers JD. Treatment of cytomegalovirus pneumonia with high-dose acyclovir. Am J Med 1982;73:249-56.
62. Wade JC, McGuffin RW, Springmeyer SC, Newton B, Singer JW, Meyers JD. Treatment of cytomegaloviral pneumonia with high-dose acyclovir and human leukocyte interferon. J Infect Dis 1983;148:557-62.
63. Reed EC, Bowden RA, Dandlinker PS, Gleaves CA, Meyers JD. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. J Infect Dis 1987;156:641-5.
64. Reed EC, Shepp DH, Dandlinker PS, Meyers JD. Ganciclovir treatment of cytomegalovirus infection of the gastrointestinal tract after marrow transplantation. Bone Marrow Transplant 1988;3:199-206.
65. Reed EC, Wolford JL, Kopeckey KJ, Lilleby KE, Dandlinker PS, Todaro JL, et al. Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. Ann Intern Med 1990;112: 505-10.
66. Shepp DH, Dandlinker PS, De Miranda P, Burnette TC, Cederberg DM, Kirk LD, et al. Activity of 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl] guanine in the treatment of cytomegalovirus pneumonia. Ann Intern Med 1985;103:368-73.
67. Reed EC, Dandlinker PS, Meyers JD. Treatment of cytomegalovirus with 9-[2-hydroxy-1-(hydroxymethyl)ethoxymethyl] guanine and high dose corticosteroids (brief report). Ann Intern Med 1986;105:214-15.
68. Winston DJ, Ho WG, Bartoni K, Holland GN, Mitsuyasu RT, Gale RP, et al. Ganciclovir therapy for cytomegalovirus infections in recipients of bone marrow transplants and other immunosuppressed patients. Rev Infect Dis 1988;10(suppl 3):S547-53.
69. Crumpacker C, Marlowe S, Zhang JL, Abrams S, Watkins P, et al. Treatment of cytomegalovirus pneumonia. Rev Infect Dis 1988;10(suppl 3):S538-46.
70. Ettinger NA, Selby P, Powles R, Milliken S, Gallagher C, Jameson B, et al. Cytomegalovirus pneumonia: the use of ganciclovir in marrow transplant recipients. J Antimicrob Chemother 1989;24:53-62.
71. Thomson MH, Jeffries DJ. Ganciclovir therapy in iatrogenically immunosuppressed patients with cytomegalovirus disease. J Antimicrob Chemother 1989;23(suppl E):61-70.
72. Ho WG, Winston DJ, Champlin RE. Tolerance and efficacy of ganciclovir in the treatment of cytomegalovirus infections in immunosuppressed patients. Transplant Proc 1989;21:3103-6.
73. Aschan J, Ringden O, Ljungman P, Lonnqvist B, Ohlman S. Foscarnet for treatment of cytomegalovirus infections in bone marrow transplant recipients. Scand J Infect Dis 1992;24:143-50.
74. Verdonck JF, de Cast GC, Dekker AW, de Weger RA, Schuurman HJ, Rozenberg-Arska M. Treatment of cytomegalovirus pneumonia after bone marrow transplantation with cytomegalovirus immunoglobulin combined with ganciclovir. Bone Marrow Transplant 1989;4:187-9.
75. Schmidt GM, Kovacs A, Zaia JA, Horak AD, Blume KG, Nademanee AP, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988;46:905-7.
76. Emanuel D, Cunningham I, Jules-Elysee K, Brochstein JA, Kernan NA, Laver J, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988;109:777-82.
77. Reed EC, Bowden RA, Dandlinker PS, Lilleby KE, Meyers JD. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988;109:783-8.
78. Ljungman P, Engelhard D, Link H, Biron P, Brandt L, Brunet S, et al. Treatment of interstitial pneumonitis due to cytomegalovirus with ganciclovir and intravenous immune globulin: experience of European Bone Marrow Transplant Group. Clin Infect Dis 1992;14:831-5.
79. Einsele H, Ehninger G, Steidle M, Vallbracht A, Muller M, Schmidt H, et al. Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease. Lancet 1991;338:1170-2.